Company news
AdAlta Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Prospectus
May 4, 2025
Renounceable Rights Issue to Raise up to $1.3 million
May 1, 2025
Trading Halt
April 29, 2025
SYNBV invest up to $2m in East to West subsidiary
March 19, 2025
R&D Tax Incentive advance received
March 4, 2025
Investor Presentation
February 6, 2025
East to West cell therapy strategy update
February 5, 2025
AD-214 clinical advisory board
October 9, 2024
FY24 RDTI Refund Received $1.77m
October 3, 2024
Transaction, investment facility update
September 2, 2024
$1.9 million raised from exercise of 1ADOA options
June 2, 2024
Cellular immunotherapy manufacturer secured - Cell Therapies
May 12, 2024
Extension of Victorian Government RDTI Loan Facility
April 28, 2024
Institutional investment to pursue strategic initiatives
April 28, 2024
SYNBV MoU Webinar presentation
April 9, 2024
SYNThesis BioVentures MoU for cellular immunotherapies
April 7, 2024
Corporate Presentation
March 7, 2024
Positive AD-214 Phase I extension study results
March 5, 2024
January 2024 partnering presentations and progress
January 21, 2024
New malaria inhibiting i-body
December 18, 2023
Chair address and CEO presentation to AGM
November 21, 2023
AD-214 Phase I extension clinical study - interim results
November 20, 2023
AdAlta closes oversubscribed $1.65 million raise
November 8, 2023
Oversubscribed placement result
November 6, 2023
Placement to raise up to $1.23million
November 2, 2023
AD-214 well tolerated in Phase I extension study
October 22, 2023
R&D tax refund received & R&D Loan repayment terms extended
October 17, 2023
Prof Foley invited presentation AD-214
September 25, 2023
Dosing simulations support AD-214 IV product profile
September 24, 2023
AD-214 Phase I extension study fully enrolled
September 19, 2023
AdAlta to Present at August 24th Virtual Investor Summit
August 16, 2023
AD-214 returns to clinic
August 3, 2023
$1.87 million raised in oversubscribed Shortfall facility
July 12, 2023
New AD-214 data de-risks clinical studies
July 6, 2023
AD-214 clinical trial approval
June 28, 2023
AdAlta to present at June 1 Virtual Investor Summit
May 30, 2023
AdAlta secures A$1.28 million in rights offer to advance AD-214
May 25, 2023
Rights Offer results
May 24, 2023
AdAlta to support early return to clinical trials of AD-214 with rights offer
May 1, 2023
Rights Offer to fund early return to clinic and growth
April 27, 2023
Publication highlights I-body potential in osteoporosis
January 24, 2023
AdAlta welcomes new substantial shareholders
January 23, 2023
Second Japan patent for AD-214
January 9, 2023
AD-214 progress and priorities webinar presentation
November 1, 2022
AD-214 progress and priorities
November 1, 2022
Balance of R&D Tax Incentive Refund received
October 26, 2022
1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
October 12, 2022
R&D Tax Incentive Refund received
October 3, 2022
Quarterly Appendix 4C and Activities Report
July 24, 2022
AD-214 program update, cash runway extension
July 3, 2022
Decks
The 5 newest of 84 decks. Every deck is listed under its year.
- BIOSeedin Autumn Innovation Partnering Summit 2026
Conference · 35 slides · Sep 10, 2026
- Investor Presentation (August 2026)
Investor deck · 35 slides · Aug 13, 2026
- ISCT ANZ 2026 Regional Meeting
Conference · 14 slides · Jul 20, 2026
- Investor Presentation (April 2026)
Investor deck · 16 slides · May 11, 2026
- ANZ Biologics Festival 2026
Conference · 21 slides · Feb 4, 2026